EP0225579B1 - Modulateurs de cellules contenant un polypeptide liés par covalence - Google Patents
Modulateurs de cellules contenant un polypeptide liés par covalence Download PDFInfo
- Publication number
- EP0225579B1 EP0225579B1 EP86116683A EP86116683A EP0225579B1 EP 0225579 B1 EP0225579 B1 EP 0225579B1 EP 86116683 A EP86116683 A EP 86116683A EP 86116683 A EP86116683 A EP 86116683A EP 0225579 B1 EP0225579 B1 EP 0225579B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ifn
- interferon
- plasmid
- chart
- gamma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/143—Lymphotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Claims (23)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/803,748 US4935233A (en) | 1985-12-02 | 1985-12-02 | Covalently linked polypeptide cell modulators |
US803748 | 1985-12-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0225579A2 EP0225579A2 (fr) | 1987-06-16 |
EP0225579A3 EP0225579A3 (en) | 1989-11-15 |
EP0225579B1 true EP0225579B1 (fr) | 1992-08-12 |
Family
ID=25187335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP86116683A Expired - Lifetime EP0225579B1 (fr) | 1985-12-02 | 1986-12-01 | Modulateurs de cellules contenant un polypeptide liés par covalence |
Country Status (7)
Country | Link |
---|---|
US (3) | US4935233A (fr) |
EP (1) | EP0225579B1 (fr) |
JP (3) | JP2612854B2 (fr) |
AU (1) | AU599936B2 (fr) |
CA (1) | CA1304024C (fr) |
DE (1) | DE3686397T2 (fr) |
ZA (1) | ZA869090B (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6730303B1 (en) | 1995-10-05 | 2004-05-04 | Pharmacia Corporation | Fused G-CSF and IL-3 proteins and uses thereof |
US7534585B2 (en) | 2003-07-21 | 2009-05-19 | Transgene S.A. | Multifunctional cytokines |
US7608267B2 (en) | 2003-07-21 | 2009-10-27 | Transgene S.A. | Multifunctional cytokines |
Families Citing this family (461)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496924A (en) * | 1985-11-27 | 1996-03-05 | Hoechst Aktiengesellschaft | Fusion protein comprising an interleukin-2 fragment ballast portion |
US5359035A (en) * | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
DE3607835A1 (de) * | 1986-03-10 | 1987-09-24 | Boehringer Ingelheim Int | Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung |
EP0237019A3 (fr) * | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Interféron conjugué et sa préparation à partir d'un gène recombinant |
JP2561122B2 (ja) * | 1988-04-13 | 1996-12-04 | 寳酒造株式会社 | 機能性ポリペプチド |
US5705478A (en) * | 1989-02-21 | 1998-01-06 | Washington University | Covalently linked β subunits of the glycoprotein hormones as antagonists |
AU5355790A (en) * | 1989-04-19 | 1990-11-16 | Cetus Corporation | Multifunctional m-csf proteins and genes encoding therefor |
US7264944B1 (en) | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
DE59010941D1 (de) * | 1989-04-21 | 2005-03-24 | Amgen Inc | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
EP0482068A1 (fr) * | 1989-07-14 | 1992-04-29 | American Cyanamid Company | Cytokine et supports d'hormone pour vaccins conjugues |
US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5108910A (en) * | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
US5945397A (en) * | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
DK0939121T4 (da) | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
ZA912490B (en) * | 1990-04-19 | 1992-12-30 | Res Dev Foundation | Antibody conjugates for treatment of neoplastic disease |
US5238823A (en) * | 1990-08-22 | 1993-08-24 | Veterinary Infectious Disease Organization | Interleukin-2-leukotoxin gene fusions and uses thereof |
US5594107A (en) * | 1990-08-22 | 1997-01-14 | University Of Saskatchewan | Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon |
US5273889A (en) * | 1990-08-22 | 1993-12-28 | University Of Saskatchewan | Gamma-iterferon-leukotoxin gene fusions and uses thereof |
CA2089553C (fr) * | 1990-08-29 | 2000-06-27 | Paul Schendel | Stimulateurs multidomaine de l'hematopoiese |
EP0503050A4 (en) * | 1990-09-28 | 1994-07-06 | Ortho Pharma Corp | Hybrid growth factors |
WO1992006117A1 (fr) * | 1990-09-28 | 1992-04-16 | Seragen, Inc. | Inhibition de reponses immunes indesirees |
US5674849A (en) * | 1990-10-24 | 1997-10-07 | Allelix Biopharmaceuticals Inc. | Anti-viral compositions |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
AU1372692A (en) * | 1991-02-08 | 1992-09-07 | Immunex Corporation | Method of inhibiting replication of hiv in macrophages |
US5661008A (en) * | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
EP0575545B1 (fr) * | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation de polypeptides |
SE468050C (sv) * | 1991-03-15 | 1998-02-11 | Pharmacia & Upjohn Ab | Rekombinant derivat av human faktor VIII |
EP1413587A2 (fr) | 1991-05-03 | 2004-04-28 | Washington University | Régulateur modifié du système de complément |
US5856115A (en) * | 1991-05-24 | 1999-01-05 | Fred Hutchinson Cancer Research Center | Assay for identification therapeutic agents |
ATE173763T1 (de) * | 1991-08-30 | 1998-12-15 | Hutchinson Fred Cancer Res | Hybride cytokine |
US6171824B1 (en) * | 1991-08-30 | 2001-01-09 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
US6028177A (en) * | 1991-10-04 | 2000-02-22 | Washington University | Methods of detecting single-chain forms of the glycoprotein hormone quartet |
US5376367A (en) * | 1991-11-22 | 1994-12-27 | Immunex Corporation | Fusion proteins comprising MGF and IL-3 |
WO1993019777A1 (fr) * | 1992-03-30 | 1993-10-14 | Immunex Corporation | Proteines de fusion comprenant un recepteur de facteur de necrose tumorale |
US5684136A (en) * | 1992-05-18 | 1997-11-04 | Genentech, Inc. | Chimeric hepatocyte growth factor (HGF) ligand variants |
ES2257734T3 (es) * | 1992-05-18 | 2006-08-01 | Genentech, Inc. | Activacion de los receptores de oligomerizacion por medio de los ligandos de receptores fusionados. |
US7166423B1 (en) * | 1992-10-21 | 2007-01-23 | Miltenyi Biotec Gmbh | Direct selection of cells by secretion product |
KR100306635B1 (ko) * | 1992-10-21 | 2001-11-30 | 스테판밀테니 | 분비생성물에의한직접적인세포선별 |
IL107642A0 (en) * | 1992-11-20 | 1994-02-27 | Amgen Inc | Progenitor b cell stimulating factor |
US6153183A (en) * | 1992-11-24 | 2000-11-28 | G. D. Searle & Company | Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production |
US5772992A (en) * | 1992-11-24 | 1998-06-30 | G.D. Searle & Co. | Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors |
ZA942206B (en) * | 1993-04-01 | 1994-10-31 | Amgen Inc | Biologically active polypeptide fusion dimers |
US6642032B2 (en) | 1993-04-14 | 2003-11-04 | Commonwealth Scientific And Industrial Research Organisation | Uses of avian interferon gamma (IFN-γ) |
AUPN154295A0 (en) * | 1995-03-06 | 1995-03-30 | Commonwealth Scientific And Industrial Research Organisation | Nucleic acid molecule encoding a protein with avian gamma-interferon activity |
KR100274186B1 (ko) * | 1993-12-22 | 2000-12-15 | 성재갑 | 싸이모신-알파와 다른 싸이토킨이 융합된 융합 단백질 |
WO1995028427A1 (fr) * | 1994-04-15 | 1995-10-26 | Imclone Systems Incorporated | Lymphokine chimere composee de l'interleukine 3 et d'une muteine de l'interleukine 6 |
US5632983A (en) * | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
US5783404A (en) | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
MX9801687A (es) | 1995-09-01 | 1998-11-29 | Corixa Corp | Compuestos y metodos para el diagnostico de tuberculosis. |
US6290969B1 (en) * | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6592877B1 (en) * | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
EP0851927B1 (fr) | 1995-09-01 | 2003-10-22 | Corixa Corporation | Composes d'immunotherapie et de diagnostic de la tuberculose |
TW555765B (en) * | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
US5753243A (en) * | 1996-10-31 | 1998-05-19 | Cosmolab, Inc. | Plasticized high water content cosmetic gel composition and pencil therefore |
DE69724451T2 (de) | 1996-12-06 | 2004-03-18 | Amgen Inc., Thousand Oaks | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen |
AU737910B2 (en) * | 1997-01-31 | 2001-09-06 | Regents Of The University Of California, The | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
US6261562B1 (en) | 1997-02-25 | 2001-07-17 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
TR199902053T2 (xx) | 1997-02-25 | 2000-04-21 | Corixa Corporation | Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar. |
US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
US6613881B1 (en) | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
US7087713B2 (en) * | 2000-02-25 | 2006-08-08 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
US6242570B1 (en) | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US6187564B1 (en) | 1997-07-10 | 2001-02-13 | Beth Israel Deaconess Medical Center | DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics |
EP1032422A4 (fr) * | 1997-11-18 | 2003-02-05 | Univ South Carolina | Unites supports d'un antigene droite |
WO1999029732A2 (fr) | 1997-12-08 | 1999-06-17 | Lexigen Pharmaceuticals Corporation | Proteines de fusion heterodymeres utiles en therapie immune ciblee et a une stimulation immune generale |
JP2002507387A (ja) | 1997-12-24 | 2002-03-12 | コリクサ コーポレイション | 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法 |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
EP1792988A3 (fr) | 1998-03-18 | 2007-08-22 | Corixa Corporation | Composés et méthodes thérapeutiques et diagnostiques du cancer du poumon |
DE69931908T2 (de) * | 1998-04-15 | 2007-01-11 | Lexigen Pharmaceuticals Corp., Lexington | Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor |
NZ509974A (en) | 1998-08-07 | 2003-10-31 | Univ Washington | Immunological herpes simplex virus antigens and methods for use thereof |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
SI1121382T1 (sl) * | 1998-10-16 | 2007-02-28 | Biogen Idec Inc | Fuzijski proteini interferona-beta in uporabe |
PL200586B1 (pl) | 1998-10-16 | 2009-01-30 | Biogen Idec Inc | Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów |
AU762616B2 (en) | 1998-10-16 | 2003-07-03 | Biogen Ma Inc. | Polymer conjugates of interferon beta-1a and uses |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1144642B1 (fr) | 1998-12-08 | 2010-05-26 | Corixa Corporation | Composes et procedes pour le traitement et le diagnostic d'infections par le chlamydia |
US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6579973B1 (en) | 1998-12-28 | 2003-06-17 | Corixa Corporation | Compositions for the treatment and diagnosis of breast cancer and methods for their use |
CZ20013527A3 (cs) | 1999-04-02 | 2002-10-16 | Corixa Corporation | Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic |
US8143386B2 (en) * | 1999-04-07 | 2012-03-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
DK1187852T3 (da) * | 1999-05-19 | 2007-11-26 | Merck Patent Gmbh | Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner |
US6319691B1 (en) * | 1999-06-15 | 2001-11-20 | Usa Universe Bioengineering, Inc. | Fusion proteins comprising IFN-alpha2b and TM-alpha1 |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
CA2386841A1 (fr) * | 1999-10-07 | 2001-04-12 | Corixa Corporation | Proteines hybrides de mycobacterium tuberculosis |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
JP2003514552A (ja) | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改善された性質を有するエリトロポエチンの形態 |
DE19957838C2 (de) * | 1999-11-25 | 2002-11-21 | Pette Heinrich Inst | Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden |
ES2433011T3 (es) | 1999-12-20 | 2013-12-05 | Immunex Corporation | Receptor TWEAK |
EP1252192B1 (fr) | 2000-02-11 | 2006-08-16 | MERCK PATENT GmbH | Amelioration de la demi-vie circulante de proteines de fusion a base d'anticorps |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
EP1278855B1 (fr) | 2000-04-21 | 2008-03-12 | Corixa Corporation | Composes et procedes pour le traitement et le diagnostic d'une infection de chlamydia |
ES2614260T3 (es) | 2000-05-26 | 2017-05-30 | Immunex Corporation | Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos |
DK2133100T3 (da) * | 2000-06-20 | 2012-01-23 | Corixa Corp | MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf |
ATE396265T1 (de) | 2000-06-28 | 2008-06-15 | Corixa Corp | Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs |
RU2272644C2 (ru) * | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
CA2427615A1 (fr) * | 2000-10-30 | 2002-06-13 | Pharmacia Corporation | 11 alpha hydroxylase et oxydoreductase d'aspergillus ochraceus |
MXPA03004112A (es) * | 2000-11-09 | 2003-08-19 | Astrazeneca Ab | Composicion farmaceutica oral que contiene un copolimero de bloque. |
ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
DK1366067T3 (da) * | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
US20030027751A1 (en) * | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
BR0209177A (pt) * | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
JP2005504513A (ja) | 2001-05-09 | 2005-02-17 | コリクサ コーポレイション | 前立腺癌の治療及び診断のための組成物及び方法 |
JP2004535202A (ja) | 2001-07-17 | 2004-11-25 | リサーチ ディベロップメント ファンデーション | アポトーシス促進性蛋白質を含む治療剤 |
PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
AU2002365279B2 (en) | 2001-12-17 | 2009-08-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
CN1639185A (zh) * | 2002-01-03 | 2005-07-13 | 斯克里普斯研究学院 | 癌相关表位 |
AU2003213118A1 (en) * | 2002-02-15 | 2003-09-09 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
GB0209896D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
JP2006506964A (ja) * | 2002-06-12 | 2006-03-02 | リサーチ ディベロップメント ファンデーション | 治療剤としての免疫毒素及びその利用 |
EP1523582B1 (fr) | 2002-07-18 | 2008-11-12 | University of Washington | Purification rapide et efficace de t-lymphocytes specifiques au hsv et antigenes a hsv identifies par ce procede |
US20040136992A1 (en) | 2002-08-28 | 2004-07-15 | Burton Paul B. J. | Compositions and method for treating cardiovascular disease |
US20050059025A1 (en) * | 2002-10-07 | 2005-03-17 | Five Giralda Farms | Compositions, organisms and methodologies employing a novel human kinase |
US20040146512A1 (en) * | 2002-10-09 | 2004-07-29 | Arnon Rosenthal | Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
CN1720327A (zh) * | 2002-10-10 | 2006-01-11 | 惠氏公司 | 使用新型人激酶的组合物、生物体及方法 |
EP1575518A4 (fr) * | 2002-10-10 | 2007-08-22 | Wyeth Corp | Compositions, organismes et methodologies utilisant une nouvelle kinase humaine |
AU2003301348A1 (en) * | 2002-10-18 | 2004-05-04 | Wyeth | Compositions and methods for diagnosing and treating autoimmune disease |
US7208306B2 (en) * | 2002-10-24 | 2007-04-24 | Wyeth | Compositions employing a novel human protein phosphatase |
MXPA05005283A (es) * | 2002-11-21 | 2005-07-25 | Wyeth Corp | Metodos para diagnostico de rcc y otros tumores solidos. |
WO2004050831A2 (fr) | 2002-11-27 | 2004-06-17 | Wyeth | Compositions, organismes et procedes faisant appel a une nouvelle kinase humaine |
CA2510180C (fr) * | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Forme humanisee de l'anticorps de souris 14.18 (h14.18) se liant au gd2 et fusion de celle-ci avec il-2 |
MXPA05007295A (es) | 2003-01-06 | 2005-09-30 | Corixa Corp | Ciertos compuestos de fosfato de aminoalquil glucosaminida y su uso. |
EP1998177A3 (fr) | 2003-01-06 | 2009-02-18 | Wyeth | Compositions et procédés de diagnostic et de traitement des cancers du colon |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
US20040191818A1 (en) * | 2003-02-26 | 2004-09-30 | O'toole Margot Mary | Compositions and methods for diagnosing and treating autoimmune diseases |
KR20050106483A (ko) * | 2003-03-04 | 2005-11-09 | 와이어쓰 | 천식 또는 그 밖의 알러지성 또는 염증성 질환을 진단 및치료하기 위한 조성물 및 방법 |
EP1601684B1 (fr) | 2003-03-05 | 2014-10-15 | Dendreon Corporation | Compositions et procedes utilisant des polypeptides a cadre de lecture differents dans le traitement du cancer et de maladies infectieuses |
WO2005001092A2 (fr) * | 2003-05-20 | 2005-01-06 | Wyeth | Compositions et procedes pour diagnostiquer et traiter le cancer |
MXPA06000974A (es) | 2003-07-25 | 2006-08-31 | Amgen Inc | Antagonistas y agonistas de ldcam y metodos para su uso. |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
US7585942B2 (en) | 2003-11-25 | 2009-09-08 | Anjin Corporation | Diphtheria toxin variant |
US7576183B2 (en) * | 2003-12-24 | 2009-08-18 | Los Alamos National Security, Llc | Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
EP1699822B1 (fr) | 2003-12-30 | 2008-04-23 | MERCK PATENT GmbH | Proteines de fusion de il-7 avec des segments d'anticorps, leur préparation et utilisation |
ES2387028T3 (es) * | 2003-12-31 | 2012-09-12 | Merck Patent Gmbh | Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada |
PL1706428T3 (pl) | 2004-01-22 | 2010-02-26 | Merck Patent Gmbh | Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza |
WO2005076981A2 (fr) * | 2004-02-05 | 2005-08-25 | Board Of Regents, The University Of Texas System | Procedes et compositions lies a la differenciation neuronale |
US20050247177A1 (en) * | 2004-04-15 | 2005-11-10 | Hetcher Jason D | Table and base assembly for a power tool |
EP1766096B1 (fr) | 2004-05-25 | 2013-01-02 | Oregon Health and Science University | Vaccination du virus de l'immunodeficience humaine (vih) utilisant des vecteurs de vaccin a base de hcmv |
EP3203241A1 (fr) | 2004-07-14 | 2017-08-09 | The Regents of The University of California | Biomarqueurs pour la détection précoce du cancer des ovaires |
MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
CN101072793B (zh) * | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
WO2006083961A2 (fr) * | 2005-02-01 | 2006-08-10 | Research Development Foundation | Polypeptides ciblés |
EP1701165A1 (fr) | 2005-03-07 | 2006-09-13 | Johannes Dr. Coy | Utilisation thérapeutique et diagnostique de TKTL1, ses inhibiteurs et ses activateurs |
CN101184504A (zh) | 2005-03-31 | 2008-05-21 | 葛兰素史密丝克莱恩生物有限公司 | 针对衣原体感染的疫苗 |
MY148086A (en) * | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
CN101273055B (zh) | 2005-04-29 | 2016-03-16 | 葛兰素史密丝克莱恩生物有限公司 | 用于预防或治疗结核分枝杆菌感染的新方法 |
US7528232B2 (en) * | 2005-05-20 | 2009-05-05 | The University Of Kentucky Research Foundation | Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in crop plants |
US8227573B2 (en) * | 2005-05-20 | 2012-07-24 | University Of Kentucky Research Foundation | Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in plants |
WO2007005627A2 (fr) | 2005-07-01 | 2007-01-11 | Forsyth Dental Infirmary For Children | Essais de detection d'antigenes de la tuberculose et vaccins |
US7494788B2 (en) * | 2005-07-11 | 2009-02-24 | Molecular Kinetics, Inc. | Entropic bristle domain sequences and their use in recombinant protein production |
KR100755676B1 (ko) * | 2005-08-26 | 2007-09-05 | 삼성전자주식회사 | 밝기 향상 및 전력 제어를 지원하는 영상 표시 장치 및방법 |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
CA2628928A1 (fr) * | 2005-11-10 | 2007-05-24 | Receptor Biologix, Inc. | Proteines de fusion a intron du facteur de croissance des hepatocytes |
ATE555125T1 (de) * | 2005-12-30 | 2012-05-15 | Merck Patent Gmbh | Interleukin-12p40-varianten mit verbesserter stabilität |
EA016429B1 (ru) | 2005-12-30 | 2012-04-30 | Мерк Патент Гмбх | Антитела против cd19 с пониженной иммуногенностью |
EP1979488A4 (fr) | 2006-01-09 | 2009-05-27 | Univ California | Combinaisons immunostimulatrices de tnfrsf, tlr, nlr, rhr, du récepteur purinergique et des agonistes du récepteur de la cytokine utilisées pour les vaccins et en immunothérapie anti-tumorale |
EP1981905B1 (fr) | 2006-01-16 | 2016-08-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccin contre chlamydia |
US8129334B2 (en) | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
MX2008015213A (es) * | 2006-05-30 | 2008-12-09 | Dow Global Technologies Inc | Metodo de optimizacion de codon. |
WO2008027099A2 (fr) * | 2006-05-30 | 2008-03-06 | Dow Global Technologies Inc. | Optimisation de rpa |
AU2007257683A1 (en) * | 2006-06-12 | 2007-12-21 | Symphogen A/S | Pan-cell surface receptor- specific therapeutics |
JP5577543B2 (ja) | 2006-09-08 | 2014-08-27 | アムジエン・インコーポレーテツド | Il−1ファミリーバリアント |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
EP2078037A4 (fr) | 2006-11-10 | 2010-01-27 | Dimerix Bioscience Pty Ltd | Hetero-dimeres/-oligomeres de recepteur a hormone de liberation de la thyrotropine et de recepteur a orexine |
WO2008124647A2 (fr) | 2007-04-04 | 2008-10-16 | Infectious Disease Research Institute | Compositions immunogènes comportant des polypeptides de mycobacterium tuberculosis et des fusions de ceux-ci |
JP2010530895A (ja) * | 2007-06-21 | 2010-09-16 | アンジェリカ セラピューティックス,インク. | 修飾毒素 |
CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
BRPI0815368A2 (pt) | 2007-08-21 | 2015-02-10 | Amgen Inc | "proteinas c-fms humanas a antigeno" |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
BRPI0818033A2 (pt) * | 2007-10-16 | 2015-03-24 | Symphogen As | Composições compreendendo multímeros otimizados de her1 e her3 e métodos para usos dos mesmos |
WO2009064944A2 (fr) | 2007-11-16 | 2009-05-22 | Nuvelo, Inc. | Anticorps dirigés contre lrp6 |
WO2009110944A1 (fr) | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Toxines modifiées |
JP5756751B2 (ja) | 2008-06-26 | 2015-07-29 | エータイアー ファーマ, インコーポレイテッド | 非正準的な生物学的活性を有するグリシル−tRNA合成酵素を含む組成物および方法 |
AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
EA027693B1 (ru) | 2008-09-26 | 2017-08-31 | Токаджен Инк. | Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации |
US10131693B2 (en) | 2008-10-20 | 2018-11-20 | Gwangju Institute Of Science And Technology | Bipodal-peptide binder |
JP2012508017A (ja) | 2008-11-07 | 2012-04-05 | ファブラス エルエルシー | 抗dll4抗体及びその使用 |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
JP5670346B2 (ja) | 2008-12-23 | 2015-02-18 | マトリックス ジェネティクス, エルエルシー | グリコーゲンが低減した、改変された光合成微生物および炭素ベースの生成物を生成することにおけるその使用 |
EP2382321A4 (fr) | 2009-01-08 | 2012-12-19 | Bio Rad Laboratories | Procédés et compositions pour améliorer l'efficacité de réactions d'amplification d'acides nucléiques |
US20120004185A1 (en) | 2009-02-27 | 2012-01-05 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
DK3255146T3 (da) | 2009-03-16 | 2019-08-19 | Pangu Biopharma Ltd | Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter |
EP2408816B1 (fr) | 2009-03-20 | 2019-09-04 | Amgen Inc. | Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7 |
AU2010236913B2 (en) | 2009-03-31 | 2016-03-24 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-tRNA synthetases having non-canonical biological activities |
CA2759611C (fr) | 2009-04-22 | 2018-11-13 | Indiana University Research And Technology Corporation | Compositions destinees au traitement des bronchopneumopathies chroniques obstructives et de l'asthme |
US20120213744A1 (en) | 2009-04-27 | 2012-08-23 | Ottawa Hospital Research Institute | Compositions and methods for modulating stem cells and uses thereof |
US20120258104A1 (en) | 2009-07-22 | 2012-10-11 | Cenix Bioscience Gmbh | Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes |
MX2012001283A (es) | 2009-07-31 | 2012-06-12 | Amgen Inc | Polipeptidos que se enlazan al inhibidor de tejidos de metaloproteinasa tipo tres (timp-3) composiciones y metodos. |
EP2464664B1 (fr) | 2009-08-13 | 2015-09-23 | Crucell Holland B.V. | Anticorps contre le virus respiratoire syncytial (vrs) humain et procédés d'utilisation |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
US20150359850A1 (en) | 2009-11-25 | 2015-12-17 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
EP2509625B1 (fr) | 2009-12-11 | 2015-01-28 | Atyr Pharma, Inc. | HISTIDYL-ARNt SYNTHÉTASES DESTINÉES À RÉDUIRE L'INFLAMMATION |
WO2011072266A2 (fr) | 2009-12-11 | 2011-06-16 | Atyr Pharma, Inc. | Aminoacyl-arnt synthétases destinées à moduler l'hématopoïèse |
JP6010463B2 (ja) | 2010-01-27 | 2016-10-19 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 改変された結核抗原 |
US8846603B2 (en) | 2010-03-12 | 2014-09-30 | Synageva Biopharma Corp. | NPP1 fusion proteins |
US8980613B2 (en) | 2010-04-06 | 2015-03-17 | Matrix Genetics, Llc | Modified photosynthetic microorganisms for producing lipids |
EP2556086B1 (fr) | 2010-04-09 | 2015-03-04 | Amgen Inc. | Protéines btnl9, acides nucléiques, et anticorps et leurs utilisations |
EP2558497A2 (fr) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Protéines de liaison au récepteur de fgf humain et à beta-klotho |
EP2591000B1 (fr) | 2010-07-09 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Anticorps anti-virus respiratoire syncytial (rsv) humain et procédés d'utilisation |
EP2606066A1 (fr) | 2010-08-16 | 2013-06-26 | Amgen Inc. | Anticorps se liant à la myostatine, compositions et procédés |
RU2013115927A (ru) | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ |
US20130345079A1 (en) | 2010-10-27 | 2013-12-26 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
EP3838922A1 (fr) | 2010-10-27 | 2021-06-23 | Amgen Inc. | Anticorps dkk1 et procédés d'utilisation |
WO2012064659A1 (fr) | 2010-11-08 | 2012-05-18 | Infectious Disease Research Institute | Vaccins comprenant des polypeptides d'hydrolase nucléosidique et de stérol 24-c-méthyltransférase (smt) non spécifiques destinés à traiter et à diagnostiquer la leishmaniose |
EP2655605A1 (fr) | 2010-12-20 | 2013-10-30 | Matrix Genetics, LLC | Microorganismes photosynthétiques modifiés pour la production de lipides |
WO2012087982A2 (fr) | 2010-12-20 | 2012-06-28 | Targeted Growth, Inc. | Microorganismes photosynthétiques modifiés pour produire des lipides |
KR20140038358A (ko) | 2011-01-11 | 2014-03-28 | 페이트 세러퓨틱스, 인코포레이티드 | 신규의 Wnt 조성물 및 이러한 조성물의 치료학적 용도 |
CA2821985C (fr) | 2011-01-11 | 2019-07-09 | Dimerix Bioscience Pty Ltd | Polytherapie |
US20140065172A1 (en) | 2011-01-26 | 2014-03-06 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
EP2671082B1 (fr) | 2011-02-02 | 2020-01-15 | Amgen Inc. | Méthodes et compositions associées à l'inhibition d'igf-1r |
US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
MX342810B (es) | 2011-03-03 | 2016-10-13 | Apexigen Inc | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. |
SG193024A1 (en) | 2011-03-11 | 2013-10-30 | Synageva Biopharma Corp | Npp1 fusion proteins |
EP2694670B1 (fr) | 2011-04-08 | 2017-07-19 | Bio-Rad Laboratories, Inc. | Mélanges de réaction pcr à activité non spécifique réduite |
MX339239B (es) | 2011-04-29 | 2016-05-18 | Apexigen Inc | Anticuerpos anti-cd40 y metodos de uso. |
US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
PL3138916T3 (pl) | 2011-05-27 | 2019-11-29 | Glaxosmithkline Biologicals Sa | Kompozycja immunogenna |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
US8470573B2 (en) | 2011-06-21 | 2013-06-25 | Bio-Rad Laboratories, Inc. | Hybrid polymerases having the ability to produce long amplicons |
MX2013013627A (es) | 2011-06-21 | 2014-04-25 | Oncofactor Corp | Composiciones y metodos para la terapia y diagnostico de cancer. |
JP6208658B2 (ja) | 2011-07-05 | 2017-10-04 | バイオアシス テクノロジーズ インコーポレイテッド | p97−抗体結合体および使用方法 |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
WO2013015821A1 (fr) | 2011-07-22 | 2013-01-31 | The Research Foundation Of State University Of New York | Anticorps anti-récepteur de b12-transcobalamine |
WO2013033260A1 (fr) | 2011-08-29 | 2013-03-07 | The Regents Of The University Of California | Utilisation de molécules associées au hdl pour traiter et prévenir des états pro-inflammatoires |
US9732130B2 (en) | 2011-09-16 | 2017-08-15 | Ottawa Hospital Research Institute | WNT7A compositions and method of using the same |
CA2848841A1 (fr) | 2011-09-16 | 2013-03-21 | Fate Therapeutics, Inc. | Compositions wnt et utilisations therapeutiques desdites compositions |
KR102007055B1 (ko) | 2011-09-22 | 2019-08-02 | 암젠 인크 | Cd27l 항원 결합 단백질 |
US8846034B2 (en) | 2011-10-24 | 2014-09-30 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
TWI571473B (zh) | 2011-11-02 | 2017-02-21 | 埃派斯進有限公司 | 抗kdr抗體及使用方法 |
TW201329104A (zh) | 2011-12-08 | 2013-07-16 | Amgen Inc | 人類lcat抗原結合蛋白質及其治療用途 |
CA2864177C (fr) | 2012-03-01 | 2019-11-26 | Amgen Research (Munich) Gmbh | Anticorps bispecifiques a proteine fusionnee liant l'albumine presentantune demi-vie prolongee |
EA201400993A1 (ru) | 2012-03-08 | 2015-05-29 | Галозим, Инк. | Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения |
WO2013134577A2 (fr) | 2012-03-08 | 2013-09-12 | Detectogen, Inc. | Dosages de détection d'antigène de leishmaniose et vaccins |
EP2834868B1 (fr) | 2012-04-02 | 2023-12-27 | Hydrogenics Corporation | Procédé de démarrage de pile à combustible |
HUE053362T2 (hu) | 2012-04-27 | 2021-06-28 | Novo Nordisk As | Emberi CD30-ligand antigént kötõ fehérjék |
US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
EP2847219A1 (fr) | 2012-05-07 | 2015-03-18 | Amgen Inc. | Anticorps anti-érythropoïétine |
RU2669346C2 (ru) | 2012-06-21 | 2018-10-10 | Норсвестерн Юниверсити | Частицы, конъюгированные с пептидами |
WO2014004549A2 (fr) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Protéines de liaison anti-mésothéline |
AU2013292510A1 (en) | 2012-07-19 | 2015-02-05 | Amgen Inc. | Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof |
AU2013295647B2 (en) | 2012-07-26 | 2018-02-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
EP2880156B1 (fr) | 2012-07-31 | 2017-08-23 | biOasis Technologies Inc | Protéines de maladie de stockage lysosomal déphosphorylées et leurs procédés d'utilisation |
HRP20240164T1 (hr) | 2012-08-03 | 2024-04-12 | Access To Advanced Health Institute | Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama |
JP2015529073A (ja) | 2012-08-20 | 2015-10-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物可逆性基を有するポリヌクレオチド |
US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
US9309318B2 (en) | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
CN104918957B (zh) | 2012-10-30 | 2018-11-16 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
JP6290918B2 (ja) | 2012-12-05 | 2018-03-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
WO2014114801A1 (fr) | 2013-01-25 | 2014-07-31 | Amgen Inc. | Anticorps ciblant cdh19 pour un mélanome |
JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
CN105263958B (zh) | 2013-03-13 | 2019-09-27 | 比奥阿赛斯技术有限公司 | p97片段及其应用 |
US9914907B2 (en) | 2013-03-13 | 2018-03-13 | Lumen Bioscience, Inc. | Cyanobacteria having improved photosynthetic activity |
WO2014164232A1 (fr) | 2013-03-13 | 2014-10-09 | Matrix Genetics, Llc | Cyanobactéries qui produisent des protéines d'empaquetage des lipides |
AU2014244444A1 (en) | 2013-03-14 | 2015-09-24 | Amgen Inc. | CHRDL-1 antigen binding proteins and methods of treatment |
WO2014140368A1 (fr) | 2013-03-15 | 2014-09-18 | Amgen Research (Munich) Gmbh | Constructions d'anticorps pour m2 et cd3 de grippe |
WO2014144632A2 (fr) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Anticorps anti-pac1 humains |
CA2902905A1 (fr) | 2013-03-15 | 2014-09-25 | Claude Geoffrey Davis | Toxines modifiees |
ES2753950T3 (es) | 2013-03-15 | 2020-04-15 | Amgen Res Munich Gmbh | Moléculas de unión monocatenarias que comprenden ABP del extremo N |
EP2970483A2 (fr) | 2013-03-15 | 2016-01-20 | Amgen Inc. | Procédés et compositions liés aux protéines de liaison à un antigène anti-ccr7 |
US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
US20150017162A1 (en) | 2013-03-15 | 2015-01-15 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
WO2014144553A1 (fr) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Protéines de liaison à la protéine sfrp5 (secreted frizzled-related protein 5) et méthodes de traitement |
BR112015024860B1 (pt) | 2013-03-28 | 2023-11-07 | Access To Advanced Health Institute | Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica |
DK3033102T4 (da) | 2013-08-13 | 2024-02-26 | Univ Northwestern | Peptidkonjugerede partikler |
EP3038657A2 (fr) | 2013-08-28 | 2016-07-06 | Bioasis Technologies Inc. | Conjugués comportant des régions fc modifiées pour cibler le snc et méthodes pour les utiliser |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
SG11201601770YA (en) | 2013-09-12 | 2016-04-28 | Halozyme Inc | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
WO2015077717A1 (fr) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn |
WO2015085147A1 (fr) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Typage de gènes polymorphes et détection de changements somatiques à l'aide de données de séquençage |
WO2015085230A1 (fr) | 2013-12-06 | 2015-06-11 | Bio-Rad Laboratories, Inc. | Polymérases de fusion |
CA2934073A1 (fr) | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Polytherapie comprenant un vaccin a base de neoantigenes |
AU2015274238B2 (en) | 2014-06-13 | 2020-11-05 | Csl Limited | Improved production of recombinant von Willebrand factor in a bioreactor |
BE1022949B1 (fr) | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
EP3172332B1 (fr) | 2014-07-22 | 2020-10-14 | Bio-rad Laboratories, Inc. | Tampons pour une utilisation avec des polymérases |
TW201609812A (zh) | 2014-07-31 | 2016-03-16 | 安美基研究(慕尼黑)公司 | 最佳化之跨物種特異性雙特異性單鏈抗體構築體 |
AR101669A1 (es) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
WO2016016415A1 (fr) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Construction d'anticorps monocaténaires bispécifiques avec distribution tissulaire améliorée |
WO2016040767A2 (fr) | 2014-09-12 | 2016-03-17 | Amgen Inc. | Anticorps et épitopes chrdl-1 |
JP2017529078A (ja) | 2014-09-15 | 2017-10-05 | リライアンス ホールディング ユーエスエー, インコーポレイテッド | 光合成の活動を改善している藍藻(シアノバクテリア) |
PL3207130T3 (pl) | 2014-10-14 | 2020-02-28 | Halozyme, Inc. | Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania |
CN105669863B (zh) | 2014-12-05 | 2019-09-13 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其应用 |
WO2016100803A2 (fr) | 2014-12-19 | 2016-06-23 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement d'une calcification tissulaire |
EP3757211A1 (fr) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Procédés pour le profilage de répertoire de récepteurs de lymphocytes t |
EP3234193B1 (fr) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Biomarqueurs moléculaires pour l'immunothérapie d'un cancer |
CN107531755B (zh) | 2015-01-16 | 2022-02-25 | 美侬米克国际有限公司 | 磷脂酰肌醇蛋白聚糖表位及其用途 |
MX2017013348A (es) | 2015-04-17 | 2018-08-01 | Amgen Res Munich Gmbh | Construcciones de anticuerpos biespecificos contra cdh3 y cd3. |
WO2016184784A1 (fr) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Peptides comprenant le domaine de liaison des protéines de plasmodium falciparum (cbp1 et cbp2) à cx3cl1 de chimiokine |
RU2020132040A (ru) | 2015-05-20 | 2020-10-12 | Те Брод Инститьют Инк. | Общие неоантигены |
TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Cd70及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
CA2997444A1 (fr) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Inhibiteur d'asgr destine a reduire les taux de cholesterol |
US10364420B2 (en) | 2015-12-07 | 2019-07-30 | Bio-Rad Laboratories, Inc | Dimeric reverse transcriptase |
CA3008892A1 (fr) | 2015-12-23 | 2017-06-29 | Cour Pharmaceuticals Development Company Inc. | Particules conjuguees par covalence de type polymere-antigene |
TWI797073B (zh) | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | 包含雙特異性抗體建構物之醫藥組合物 |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
CN114716557A (zh) | 2016-02-03 | 2022-07-08 | 安进研发(慕尼黑)股份有限公司 | Psma和cd3双特异性t细胞接合抗体构建体 |
MA43955B1 (fr) | 2016-02-03 | 2022-02-28 | Amgen Inc | Anticorps anti-bcma et anti-cd3 bispécifiques de format bite |
JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド (エイチケイ) リミテッド | 多重特異性Fab融合タンパクおよびその使用 |
WO2017161206A1 (fr) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation |
WO2017184590A1 (fr) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Prédiction améliorée d'épitope hla |
JOP20170091B1 (ar) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
CN109310748A (zh) | 2016-05-21 | 2019-02-05 | 传染病研究所 | 用于治疗继发性结核和非结核分枝杆菌感染的组合物和方法 |
TWI826351B (zh) | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧(杭州)生物醫藥有限公司 | R抗體,其藥物組合物及其應用 |
US11364284B2 (en) | 2016-06-16 | 2022-06-21 | Inozyme Pharma, Inc. | Methods of treating myointimal proliferation |
WO2018022967A1 (fr) | 2016-07-28 | 2018-02-01 | Regeneron Pharmaceuticals, Inc. | Variants de gpr156 et leurs utilisations |
TWI765900B (zh) | 2016-08-03 | 2022-06-01 | 中國大陸商軒竹(北京)醫藥科技有限公司 | 哌唑黴素(plazomicin)抗體及使用方法 |
CA3034094A1 (fr) | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Variants d'endonuclease de homing du recepteur alpha de l'il-10, compositions et methodes d'utilisation associees |
US11630103B2 (en) | 2016-08-17 | 2023-04-18 | The Broad Institute, Inc. | Product and methods useful for modulating and evaluating immune responses |
US20190262398A1 (en) | 2016-08-23 | 2019-08-29 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
IL265045B2 (en) | 2016-09-08 | 2023-09-01 | Bluebird Bio Inc | Variants of endonuclease pd-1, compositions and methods of use |
US11801290B2 (en) | 2016-09-16 | 2023-10-31 | Access To Advanced Health Institute | Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
EP3518966A1 (fr) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions et méthodes de traitement d'une infection par hpv persistante |
EP3526334A4 (fr) | 2016-10-17 | 2020-09-30 | Bluebird Bio, Inc. | Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation |
AU2017362484B2 (en) | 2016-11-17 | 2021-12-16 | 2Seventy Bio, Inc. | TGFβ signal convertor |
SG11201906735RA (en) | 2017-01-23 | 2019-08-27 | Regeneron Pharma | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
WO2018140391A1 (fr) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions et procédés de détection d'un variant mutant d'un polynucléotide |
JOP20190189A1 (ar) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
ES2965475T3 (es) | 2017-02-12 | 2024-04-15 | Biontech Us Inc | Métodos y composiciones basados en HLA y usos de los mismos |
EP4317447A3 (fr) | 2017-02-15 | 2024-05-01 | 2seventy bio, Inc. | Modèles de réparation de donneur pour l'édition du génome multiplex |
EP3583207A4 (fr) | 2017-02-16 | 2020-11-18 | Bio-Rad Laboratories, Inc. | Nouvelles transcriptases inverses et leurs utilisations |
WO2018195338A1 (fr) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions et procédés pour le traitement d'inflammation pulmonaire |
CA3060856A1 (fr) | 2017-05-05 | 2018-11-08 | Amgen Inc. | Composition pharmaceutique comprenant des constructions d'anticorps bispecifiques pour un stockage et une administration ameliores |
AU2018270088A1 (en) | 2017-05-18 | 2020-01-16 | Massachusetts Institute Of Technology | Systems, methods, and compositions for targeted nucleic acid editing |
MA48797A (fr) | 2017-05-25 | 2020-04-08 | Bluebird Bio Inc | Variants de l'endonucléase cblb , compositions et procédés d'utilisation |
CA3065938A1 (fr) | 2017-06-05 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Variants de b4galt1 et utilisations associees |
AU2018290843A1 (en) | 2017-06-26 | 2020-01-16 | Massachusetts Institute Of Technology | CRISPR/Cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
WO2019006455A1 (fr) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | Auxiliaires de phosphoramidites chiraux et leurs procédés d'utilisation |
KR20200038309A (ko) | 2017-08-23 | 2020-04-10 | 체에스엘 베링 게엠베하 | 폰 빌레브란트 인자의 바이러스 여과 방법 |
EP3679158A1 (fr) | 2017-09-06 | 2020-07-15 | Regeneron Pharmaceuticals, Inc. | Variants apparentés au récepteur de l'interleukine 1 d'immunoglobuline unique (sigirr) et leurs utilisations |
WO2019051033A1 (fr) | 2017-09-07 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | Variants du membre 1 de la famille 14 des transporteurs de solutés (slc14a1) et leurs utilisations |
MA50239A (fr) | 2017-09-15 | 2020-07-22 | Amgen Inc | Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique |
CA3075849A1 (fr) | 2017-09-19 | 2019-03-28 | Advaxis, Inc. | Compositions et procedes de lyophilisation de bacteries ou de souches de listeria |
CN111511388A (zh) | 2017-09-21 | 2020-08-07 | 博德研究所 | 用于靶向核酸编辑的系统、方法和组合物 |
CA3096821A1 (fr) | 2017-09-27 | 2019-04-04 | Inozyme Pharma, Inc. | Methodes d'amelioration de la fonction cardio-vasculaire et de traitement d'une maladie cardio-vasculaire a l'aide d'une ecto-nucleotide pyrophosphatase/phosphodiesterase recombin ante |
EP3461497A1 (fr) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Antigènes viraux |
MA50360A (fr) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences Inc | Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations |
EP3697807A1 (fr) | 2017-10-16 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Variants de cornulin (crnn) et leurs utilisations |
KR20200074201A (ko) | 2017-11-02 | 2020-06-24 | 바이엘 악티엔게젤샤프트 | Alk-1 및 bmpr-2에 결합하는 이중특이적 항체 |
BR112020011627A2 (pt) | 2017-12-11 | 2020-11-17 | Amgen Inc. | processo de fabricação contínuo para produtos de anticorpos biespecíficos |
EP3723787A4 (fr) | 2017-12-14 | 2021-09-01 | Bluebird Bio, Inc. | Récepteurs de l'interleukine darique |
UY38041A (es) | 2017-12-29 | 2019-06-28 | Amgen Inc | Construcción de anticuerpo biespecífico dirigida a muc17 y cd3 |
AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
CA3091352A1 (fr) | 2018-02-21 | 2019-08-29 | The University Of Montana | Composes de trehalose de diaryle et leurs utilisations |
US11572381B2 (en) | 2018-03-02 | 2023-02-07 | The University Of Montana | Immunogenic trehalose compounds and uses thereof |
CA3093467C (fr) | 2018-03-09 | 2022-12-06 | Advaxis, Inc. | Compositions et methodes d'evaluation d'attenuation et d'infectivite de souches de listeria |
CN117126279A (zh) | 2018-03-20 | 2023-11-28 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
CN110357959B (zh) | 2018-04-10 | 2023-02-28 | 鸿运华宁(杭州)生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
EP3785029A1 (fr) | 2018-04-27 | 2021-03-03 | Advaxis, Inc. | Compositions et procédés d'évaluation de la puissance d'agents immunothérapeutiques à base de listeria |
KR102167755B1 (ko) | 2018-05-23 | 2020-10-19 | 주식회사 큐어바이오 | 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도 |
SG11202010025YA (en) | 2018-05-31 | 2020-11-27 | Glyconex Inc | Therapeutic antibodies binding to biantennary lewis b and lewis y antigens |
CN110655577A (zh) | 2018-06-13 | 2020-01-07 | 鸿运华宁(杭州)生物医药有限公司 | APJ抗体及其与Elabela的融合蛋白质,以及其药物组合物和应用 |
WO2020023300A1 (fr) | 2018-07-22 | 2020-01-30 | Bioasis Technologies, Inc. | Traitement de métastases lymphatiques |
TW202021616A (zh) | 2018-07-30 | 2020-06-16 | 美商安進公司 | 結合至cd33和cd3的雙特異性抗體構建體之延長投與 |
AU2019314433A1 (en) | 2018-07-31 | 2021-03-25 | Massachusetts Institute Of Technology | Novel CRISPR enzymes and systems |
MX2021001353A (es) | 2018-08-03 | 2021-04-13 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cldn18.2 y cd3. |
WO2020033601A1 (fr) | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Nouveaux systèmes et enzymes cas12b |
EP3856781A1 (fr) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Anticorps dirigés contre bcma soluble |
WO2020072700A1 (fr) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Lignées d'allèles uniques d'alh |
WO2020072059A1 (fr) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Variants de l'endonucléase cblb, compositions et méthodes d'utilisation |
US20210395298A1 (en) | 2018-10-11 | 2021-12-23 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
CA3124110A1 (fr) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Systemes de transposases associes a crispr et procedes d'utilisation correspondants |
MX2021007556A (es) | 2018-12-21 | 2021-09-10 | Biontech Us Inc | Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
CN113661239A (zh) | 2018-12-28 | 2021-11-16 | 催化剂生物科学公司 | 经修饰的尿激酶型纤溶酶原激活物多肽和使用方法 |
WO2020172293A1 (fr) | 2019-02-20 | 2020-08-27 | Amgen Inc. | Procédés de détermination de la stabilité de protéines |
EP3947446A1 (fr) | 2019-03-25 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Traitement de troubles de tauopathie par ciblage de nouvelles espèces tau |
CA3133459A1 (fr) | 2019-03-27 | 2020-10-01 | Amgen Inc. | Methodes de cartographie de proteines therapeutiques par l'intermediaire d'une technique de resonance magnetique nucleaire bidimensionnelle (2d) a une abondance naturelle pour pro duits biopharmaceutiques formules |
US20220220469A1 (en) | 2019-05-20 | 2022-07-14 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
MX2021014644A (es) | 2019-06-13 | 2022-04-06 | Amgen Inc | Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos. |
CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁(杭州)生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用 |
WO2021041922A1 (fr) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Systèmes de transposase mu associés à crispr |
WO2021050640A1 (fr) | 2019-09-10 | 2021-03-18 | Amgen Inc. | Procédé de purification de polypeptides de liaison à un antigène bispécifique présentant une capacité de liaison dynamique de capture de protéine l améliorée |
CN112521501A (zh) | 2019-09-18 | 2021-03-19 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
CN115175996A (zh) | 2019-09-20 | 2022-10-11 | 博德研究所 | 新颖vi型crispr酶和系统 |
US20220396599A1 (en) | 2019-11-13 | 2022-12-15 | Amgen Inc. | Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules |
AU2021205639A1 (en) | 2020-01-10 | 2022-07-14 | Centre National De La Recherche Scientifique - Cnrs - | Rspo1 proteins and their use |
US20230093169A1 (en) | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
US20230348624A1 (en) | 2020-01-30 | 2023-11-02 | Umoja Biopharma, Inc. | Bispecific transduction enhancer |
US11168128B2 (en) | 2020-02-26 | 2021-11-09 | Vir Biotechnology, Inc. | Antibodies against SARS-CoV-2 and methods of using the same |
WO2021183861A1 (fr) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Méthodes de traitement et de prophylaxie du crs chez des patients, comprenant une association d'anticorps bispécifiques se liant à une cellule tumorale du cds x et d'un inhibiteur du tnf alpha ou de l'il-6 |
WO2021188851A1 (fr) | 2020-03-19 | 2021-09-23 | Amgen Inc. | Anticorps contre la mucine 17 et leurs utilisations |
WO2021203053A1 (fr) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunothérapie ciblant une région conservée dans des coronavirus sras |
JP2023523549A (ja) | 2020-04-14 | 2023-06-06 | ヴィア・バイオテクノロジー・インコーポレイテッド | SARS-CoV-2に対する抗体およびそれを使用する方法 |
AU2021265108A1 (en) | 2020-04-29 | 2022-10-27 | Amgen Inc. | Pharmaceutical formulation |
KR20230004799A (ko) | 2020-04-29 | 2023-01-06 | 암젠 인크 | 제약 제형 |
WO2021224913A1 (fr) | 2020-05-04 | 2021-11-11 | Immunorizon Ltd. | Constructions d'anticorps tri-spécifiques précurseurs et leurs procédés d'utilisation |
CA3177169A1 (fr) | 2020-05-08 | 2021-11-11 | Vir Biotechnology, Inc. | Anticorps contre sars-cov-2 |
CN116903727A (zh) | 2020-05-08 | 2023-10-20 | 高山免疫科学股份有限公司 | 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法 |
US20210355468A1 (en) | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
EP4153633A1 (fr) | 2020-05-19 | 2023-03-29 | Amgen Inc. | Constructions de liaison à mageb2 |
MX2022014902A (es) | 2020-05-29 | 2023-01-04 | Amgen Inc | Administracion mitigadora de efectos adversos de un constructo biespecifico que se une a cd33 y cd3. |
WO2021247925A1 (fr) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Immunothérapie guidée par une structure dirigée contre le sars-cov-2 |
JP2023530274A (ja) | 2020-06-12 | 2023-07-14 | ヴィア・バイオテクノロジー・インコーポレイテッド | SARS-CoV-2感染の抗体療法 |
US20210393787A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
KR20230042023A (ko) | 2020-06-24 | 2023-03-27 | 비르 바이오테크놀로지, 인코포레이티드 | 조작된 b형 간염 바이러스 중화 항체 및 이의 용도 |
JP2023538669A (ja) | 2020-08-24 | 2023-09-08 | アムジェン インコーポレイテッド | Bite、二重特異性抗体、及びメチオニンを含む医薬製剤 |
EP4217385A2 (fr) | 2020-09-28 | 2023-08-02 | VIR Biotechnology, Inc. | Anticorps contre le sars-cov-2 |
BR112023008670A2 (pt) | 2020-11-06 | 2024-02-06 | Amgen Inc | Construtos polipeptídicos ligados à cd3 |
BR112023008629A2 (pt) | 2020-11-06 | 2023-10-03 | Amgen Inc | Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3 |
CN116323671A (zh) | 2020-11-06 | 2023-06-23 | 安进公司 | 具有增加的选择性的多靶向性双特异性抗原结合分子 |
IL302963A (en) | 2020-11-23 | 2023-07-01 | Vir Biotechnology Inc | Broadly neutralizing antibodies against influenza neuraminidase |
IL302938A (en) | 2020-11-23 | 2023-07-01 | Vir Biotechnology Inc | Antibodies against influenza A viruses |
US20240141021A1 (en) | 2020-11-23 | 2024-05-02 | Vir Biotechnology, Inc. | Anti-influenza antibodies and combinations thereof |
TW202235107A (zh) | 2020-11-25 | 2022-09-16 | 美商維爾生物科技股份有限公司 | 結合至多種乙型冠狀病毒的抗體 |
JP2024502630A (ja) | 2021-01-12 | 2024-01-22 | マーチ セラピューティクス, インコーポレイテッド | コンテキスト依存性二本鎖dna特異的デアミナーゼ及びその使用 |
WO2022171121A1 (fr) | 2021-02-10 | 2022-08-18 | 同润生物医药(上海)有限公司 | Méthode et combinaison pour le traitement de tumeurs |
WO2022204202A1 (fr) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Anticorps qui se lient à de multiples sarbecovirus |
CN115141276A (zh) | 2021-03-31 | 2022-10-04 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用 |
EP4070814A1 (fr) | 2021-04-07 | 2022-10-12 | Lama France | Polypeptides sars-cov-2 et leurs utilisations |
CN117279947A (zh) | 2021-05-06 | 2023-12-22 | 安进研发(慕尼黑)股份有限公司 | 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子 |
AU2022285665A1 (en) | 2021-06-01 | 2023-10-19 | Amgen Inc. | Accelerated method of making lyophilized protein formualtions |
AU2022304662A1 (en) | 2021-06-30 | 2023-11-23 | Amgen Inc. | Method of reconstituting lyophilized formulation |
CA3225626A1 (fr) | 2021-07-15 | 2023-01-19 | Diogenx | Variants recombinants de proteines r-spondine et leur utilisation |
AR126900A1 (es) | 2021-08-27 | 2023-11-29 | Humabs Biomed Sa | Polipéptidos de coronavirus modificados genéticamente, polinucleótidos, vectores y células huésped, y composiciones relacionadas |
WO2023034871A1 (fr) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | Thérapies par anticorps à haute concentration contre infection par sars-cov-2 |
CA3230613A1 (fr) | 2021-09-01 | 2023-03-09 | Daren J. AUSTIN | Therapies a base d'anticorps pour infection a sars-cov-2 chez des sujets pediatriques |
WO2023141602A2 (fr) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Rétrons modifiés et méthodes d'utilisation |
WO2023168426A1 (fr) | 2022-03-03 | 2023-09-07 | Enosi Therapeutics Corporation | Compositions et cellules contenant des mélanges de protéines de fusion oligo-trap (ofps) et leurs utilisations |
WO2023196996A2 (fr) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Récepteur multipartite et complexes de signalisation |
WO2023201256A1 (fr) | 2022-04-12 | 2023-10-19 | Vir Biotechnology, Inc. | Thérapies par anticorps à haute dose contre une infection par le sars-cov-2 |
TW202346368A (zh) | 2022-05-12 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子 |
WO2023230448A1 (fr) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Immunothérapie combinée contre la grippe |
WO2023230445A2 (fr) | 2022-05-23 | 2023-11-30 | Humabs Biomed Sa | Anticorps largement neutralisants dirigés contre la neuraminidase de la grippe |
WO2023230439A1 (fr) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Anticorps neutralisants à fc modifié contre le virus de l'hépatite b et utilisations associées |
WO2023245078A1 (fr) | 2022-06-15 | 2023-12-21 | Humabs Biomed Sa | Anticorps anti-parvovirus et leurs utilisations |
WO2024006472A1 (fr) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Anticorps qui se lient à de multiples sarbecovirus |
WO2024015892A1 (fr) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Procédés et systèmes faisant intervenir l'immunopeptidome hla-ii pour la découverte d'antigènes |
WO2024020346A2 (fr) | 2022-07-18 | 2024-01-25 | Renagade Therapeutics Management Inc. | Composants d'édition génique, systèmes et procédés d'utilisation |
WO2024026411A1 (fr) | 2022-07-27 | 2024-02-01 | Humabs Biomed Sa | Anticorps neutralisants à large spectre contre les paramyxovirus rsv et mpv |
WO2024044723A1 (fr) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Rétrons modifiés et méthodes d'utilisation |
WO2024047587A1 (fr) | 2022-08-31 | 2024-03-07 | Regel Therapeutics, Inc. | Compositions cas-phi et méthodes d'utilisation |
WO2024059675A2 (fr) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Composition de stabilisation de molécule bispécifique |
WO2024077256A1 (fr) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Procédés et compositions pour la découverte à haut débit de protéines de liaison ciblant un peptide-cmh |
WO2024086827A2 (fr) | 2022-10-20 | 2024-04-25 | Repertoire Immune Medicines, Inc. | Il2 ciblant les lymphocytes t cd8 |
WO2024092033A1 (fr) | 2022-10-26 | 2024-05-02 | Amgen Inc. | Molécules multispécifiques pour la clairance d'immunoglobulines dans le traitement de maladies induites par des auto-anticorps |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292668A (en) * | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
JPS58110548A (ja) * | 1981-12-24 | 1983-07-01 | Asahi Chem Ind Co Ltd | 新規な生理活性ペプチド |
IT1167610B (it) * | 1982-01-19 | 1987-05-13 | Cetus Corp | Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4468382A (en) * | 1982-07-15 | 1984-08-28 | New England Medical Center, Inc. | Polypeptide-toxin hybrid protein |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4921699A (en) * | 1983-06-01 | 1990-05-01 | Hoffman-La Roche Inc. | Polypeptides having interferon activity |
ZA844070B (en) * | 1983-06-01 | 1984-12-24 | Genentech Inc | Gamma interferon-lymphotoxin synergism |
GB8315980D0 (en) * | 1983-06-10 | 1983-07-13 | Biogen Nv | Producing hybrid dna sequences |
WO1985002198A1 (fr) * | 1983-11-01 | 1985-05-23 | Amgen | Expression microbienne du facteur de croissance transformant du type i, de ses analogues polypeptidiques et des polypeptides hybrides de l'egf et du tgf |
DE3476241D1 (en) * | 1983-11-18 | 1989-02-23 | Tba Industrial Products Ltd | Glass fibre products |
WO1985004420A1 (fr) * | 1984-03-29 | 1985-10-10 | Takeda Chemical Industries, Ltd. | Nouvel adn et son utilisation |
EP0158198A1 (fr) * | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | ADN et son utilisation |
US4734491A (en) * | 1984-08-31 | 1988-03-29 | University Patents, Inc. | DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons |
JPS61128889A (ja) * | 1984-11-27 | 1986-06-16 | Green Cross Corp:The | 組換えdna及び該dnaによる形質転換体 |
US4691009A (en) * | 1984-12-26 | 1987-09-01 | Repligen Corporation | Hybrid proteins produced by an ultrahigh prokaryotic expression system |
EP0237019A3 (fr) * | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Interféron conjugué et sa préparation à partir d'un gène recombinant |
-
1985
- 1985-12-02 US US06/803,748 patent/US4935233A/en not_active Expired - Lifetime
-
1986
- 1986-12-01 AU AU65851/86A patent/AU599936B2/en not_active Ceased
- 1986-12-01 EP EP86116683A patent/EP0225579B1/fr not_active Expired - Lifetime
- 1986-12-01 DE DE8686116683T patent/DE3686397T2/de not_active Expired - Fee Related
- 1986-12-01 CA CA000524201A patent/CA1304024C/fr not_active Expired - Lifetime
- 1986-12-02 JP JP61287561A patent/JP2612854B2/ja not_active Expired - Lifetime
- 1986-12-02 ZA ZA869090A patent/ZA869090B/xx unknown
-
1989
- 1989-07-13 US US07/379,509 patent/US5114711A/en not_active Expired - Lifetime
-
1995
- 1995-04-28 JP JP7106110A patent/JP2752336B2/ja not_active Expired - Lifetime
-
1996
- 1996-10-14 JP JP8271192A patent/JP2759074B2/ja not_active Expired - Lifetime
-
1999
- 1999-08-25 US US09/382,738 patent/US6545124B1/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
Watson et al. Recombinant DNA. A short course. Sci.Am.Books, pp. 75-87 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6730303B1 (en) | 1995-10-05 | 2004-05-04 | Pharmacia Corporation | Fused G-CSF and IL-3 proteins and uses thereof |
US7534585B2 (en) | 2003-07-21 | 2009-05-19 | Transgene S.A. | Multifunctional cytokines |
US7608267B2 (en) | 2003-07-21 | 2009-10-27 | Transgene S.A. | Multifunctional cytokines |
Also Published As
Publication number | Publication date |
---|---|
JPS62282593A (ja) | 1987-12-08 |
JP2612854B2 (ja) | 1997-05-21 |
AU599936B2 (en) | 1990-08-02 |
US4935233A (en) | 1990-06-19 |
JPH07313170A (ja) | 1995-12-05 |
JP2759074B2 (ja) | 1998-05-28 |
JPH09118698A (ja) | 1997-05-06 |
US6545124B1 (en) | 2003-04-08 |
JP2752336B2 (ja) | 1998-05-18 |
US5114711A (en) | 1992-05-19 |
DE3686397T2 (de) | 1992-12-17 |
EP0225579A3 (en) | 1989-11-15 |
AU6585186A (en) | 1987-06-04 |
CA1304024C (fr) | 1992-06-23 |
DE3686397D1 (de) | 1992-09-17 |
ZA869090B (en) | 1988-02-24 |
EP0225579A2 (fr) | 1987-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0225579B1 (fr) | Modulateurs de cellules contenant un polypeptide liés par covalence | |
EP0146354B2 (fr) | Gamma-interférons recombinants et composition pharmaceutique les contenant | |
US4738844A (en) | Modified (1-28) beta interferons | |
Allen et al. | A family of structural genes for human lymphoblastoid (leukocyte-type) interferon | |
US5690925A (en) | Recombinant gamma interferons having enhanced stability and methods therefor | |
US4769233A (en) | Structure and properties of modified interferons | |
Staehelin et al. | Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies. | |
US5278286A (en) | Immune interferon | |
US4604284A (en) | Homogeneous immune interferon fragment | |
KR910001726B1 (ko) | 펩티드의 제조방법 | |
Arnheiter et al. | Physicochemical and antigenic properties of synthetic fragments of human leukocyte interferon | |
KR20050107435A (ko) | 개선된 특성의 인터페론 알파 뮤테인의 융합 단백질 | |
FI80293B (fi) | Foerfarande foer framstaellning av intakt rekombinent humanimmuninterferon. | |
Greenfield et al. | Biochemical Analysis and Biological Activities of Immunoaffinity Purified Natural Murine Gamma Interferon (MuIFN‐γ) | |
Gargiulo et al. | High-titre antibodies to a foreign epitope elicited by affinity-purified hybrid LamB proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): BE CH DE FR GB IT LI NL SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PORTER, ALAN GEORGE Inventor name: MCCULLAGH, KEITH GRAHAM Inventor name: BELL, LESLIE DAVID |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): BE CH DE FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19900409 |
|
17Q | First examination report despatched |
Effective date: 19910206 |
|
ITTA | It: last paid annual fee | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB IT LI NL SE |
|
REF | Corresponds to: |
Ref document number: 3686397 Country of ref document: DE Date of ref document: 19920917 |
|
ITF | It: translation for a ep patent filed |
Owner name: BARZANO' E ZANARDO ROMA S.P.A. |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
EAL | Se: european patent in force in sweden |
Ref document number: 86116683.3 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19981118 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19981119 Year of fee payment: 13 Ref country code: GB Payment date: 19981119 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19981120 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19981126 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19981127 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19981210 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19991201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19991202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19991231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19991231 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19991231 |
|
BERE | Be: lapsed |
Owner name: G.D. SEARLE & CO. Effective date: 19991231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000701 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19991201 |
|
EUG | Se: european patent has lapsed |
Ref document number: 86116683.3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000831 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20000701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20001003 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20051201 |